Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of Furmonertinib in Advanced or Metastatic NSCLC with EGFR or HER2 Mutations
jRCT2031220455Phase 1Active, not recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of furmonertinib in EGFR-mutated non-small cell lung cancer and non-small cell lung cancer (NSCLC) (5 arms), sponsored by ArriVent BioPharma. Primary endpoints: Incidence and severity of adverse events (AEs) and Overall response rate (ORR). Started Dec 2022; status: active, not recruiting.
02
Drugs
furmonertinib
03
Conditions
EGFR-mutated non-small cell lung cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031220455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220455.